Multi-user equipment approved in grant 2013/08216-2: QuantStudio 5 Real Time PCR System Applied Biosystems

• Grant number: 21/08865-7
• Support type: Multi-user Equipment Program
• Duration: September 01, 2021 - August 31, 2028
• Field of knowledge: Biological Sciences - Pharmacology - Biochemical and Molecular Pharmacology
• Principal researcher: Fernando de Queiroz Cunha
• Grantee: Fernando de Queiroz Cunha
• Home Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated research grant: 13/08216-2 - CRID - Center for Research in Inflammatory Diseases, AP.CEPID
• EMU web page: Página do Equipamento Multiusuário não informada
• Type of equipment: Caracterização e Análises de Amostras - Proteínas/Ácidos nuclêicos - PCR
• Manufacturer: Fabricante não informado
• Model: Modelo não informado

Abstract

Inflammatory diseases are a complex and heterogeneous group of diseases that affect more than 10% of the word population. The current options for the treatment of these diseases are still limited and, in some cases, inefficient due to limited understanding of the mechanisms underlying these diseases. The development of translational research by a center that can generate scientific knowledge and also identify new therapeutic targets of inflammatory diseases is imperative. The Center for Research in Inflammatory Diseases (CRID) will be created with this goal. The general objective of the CPDI will be to perform integrative and translational research to identify, validate and target known, and novel biological pathways involved with the induction and resolution of inflammation. As a result, we expect the development of innovative therapeutic strategies and drugs that effectively target inflammatory diseases. The project will involve high-throughput genetic screenings, in vivo and in vitro models of diseases, modeling and chemical synthesis, as well as the discovery of new natural molecules from plants and saliva from arthropods. After selecting the potential drugs and bio-drugs, CRID will protect the intellectual property and, after partnerships with private companies, coordinate pre-clinical toxicological studies and early clinical trials. The CRID will also dedicate intense efforts to disseminate knowledge to the general public, in order to fulfill the societal objective of spreading education and generating an enthusiasm for science. (AU)